Menopausal status-Postmenopausal Posts on Medivizor
Navigation Menu

Menopausal status-Postmenopausal Posts on Medivizor

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Posted by on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...

Read More

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Read More

Does the histological grade of early stage breast cancer effect outcomes of older women treated with breast conserving surgery?

Does the histological grade of early stage breast cancer effect outcomes of older women treated with breast conserving surgery?

Posted by on Jan 31, 2021 in Breast cancer | 0 comments

In a nutshell This article was carried out to look at how histological grade (HG) impacts the outcomes of older women with early-stage (ES) breast cancer (BC) treated with breast-conserving therapy (BCS) with or without radiotherapy (RT). The authors found that the treatment of ESBC without RT resulted in a lower cancer-specific survival...

Read More

The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment

The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment

Posted by on Jul 5, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...

Read More

Looking for postmenopausal women with advanced breast cancer to try a hormonal therapy

Posted by on Oct 24, 2019 in Breast cancer | 0 comments

In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...

Read More

How effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?

How effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?

Posted by on Aug 14, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations.  Some background Breast cancer (BC) types can be...

Read More

Looking for patients with hormone-receptor positive breast cancer to test a new treatment combination

Looking for patients with hormone-receptor positive breast cancer to test a new treatment combination

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...

Read More

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor